1. Home
  2. STIM vs LUNG Comparison

STIM vs LUNG Comparison

Compare STIM & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuronetics Inc.

STIM

Neuronetics Inc.

N/A

Current Price

$2.34

Market Cap

120.4M

Sector

Health Care

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

N/A

Current Price

$2.76

Market Cap

97.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STIM
LUNG
Founded
2003
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
120.4M
97.1M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
STIM
LUNG
Price
$2.34
$2.76
Analyst Decision
Strong Buy
Buy
Analyst Count
4
5
Target Price
★ $6.00
$3.70
AVG Volume (30 Days)
1.1M
★ 1.1M
Earning Date
11-04-2026
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 57.25
7.64
EPS
★ N/A
N/A
Revenue
$52,776,000.00
★ $90,497,000.00
Revenue This Year
$8.63
$0.33
Revenue Next Year
$9.24
$8.68
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 8.01
52 Week Low
$0.80
$1.13
52 Week High
$3.44
$3.25

Technical Indicators

Market Signals
Indicator
STIM
LUNG
Relative Strength Index (RSI) 50.93 61.23
Support Level $1.19 $1.26
Resistance Level $2.31 $3.25
Average True Range (ATR) 0.25 0.32
MACD 0.04 0.05
Stochastic Oscillator 35.21 66.10

Price Performance

Historical Comparison
STIM
LUNG

About STIM Neuronetics Inc.

Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: